IFF · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
INTERNATIONAL FLAVORS & FRAGRANCES INC · 2026-08-04 · Importance 49 · Surprise 32 · In source text
Second-quarter 2026 continuing-operations sales increased $35 million, or 2% reported, to $1.954 billion, while comparable currency-neutral sales increased 6% year over year. Taste sales rose 5% to $688 million, Health & Biosciences rose 8% to $601 million, and Scent rose 10% to $665 million. For the first six months, reported sales declined 3% to $3.860 billion because of approximately $379 million of divestiture impacts, while comparable currency-neutral sales increased 4%. Six-month sales increased 5% in Taste to $1.368 billion, 9% in Health & Biosciences to $1.176 billion, and 8% in Scent to $1.316 billion.
Key facts
- Scent sales in Q2 2026 increased $62 million, or 10% on a reported basis, to $665 million compared to $603 million in the prior year period. source
- Taste Segment Adjusted Operating EBITDA increased $30 million, or 12% on a reported basis, to $276 million in the first six months of 2026 (20.2% of segment sales) from $246 million (18.9% of segment sales) in the comparable 2025 period. source
- Health & Biosciences Segment Adjusted Operating EBITDA increased $28 million, or 11% on a reported basis, to $290 million in the first six months of 2026 (24.7% of segment sales) from $262 million (24.3% of segment sales) in the comparable 2025 period. source
- Sales for the first six months of 2026 decreased $109 million, or 3% on a reported basis, to $3,860 million compared to $3,969 million in the 2025 period. source
- Scent Segment Adjusted Operating EBITDA increased $16 million, or 6% on a reported basis, to $275 million in the first six months of 2026 (20.9% of segment sales) from $259 million (21.3% of segment sales) in the comparable 2025 period. source
- Taste sales in Q2 2026 increased $34 million, or 5% on a reported basis, to $688 million compared to $654 million in the prior year period. source
- Health & Biosciences sales in Q2 2026 increased $42 million, or 8% on a reported basis, to $601 million compared to $559 million in the prior year period. source
- Sales in the second quarter of 2026 increased $35 million, or 2% on a reported basis, to $1,954 million compared to $1,919 million in the 2025 period. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | -5.6% | Sales for the first six months of 2026 decreased $109 million, or 3% on a reported basis, to $3,860 million compared to $3,969 million in… |
| revenue | positive | realized | +3.2% | Scent sales in Q2 2026 increased $62 million, or 10% on a reported basis, to $665 million compared to $603 million in the prior year period. |
| revenue | positive | realized | +2.1% | Health & Biosciences sales in Q2 2026 increased $42 million, or 8% on a reported basis, to $601 million compared to $559 million in the… |
| revenue | positive | realized | +1.7% | Taste sales in Q2 2026 increased $34 million, or 5% on a reported basis, to $688 million compared to $654 million in the prior year period. |
| operating_income | positive | realized | +1.5% | Taste Segment Adjusted Operating EBITDA increased $30 million, or 12% on a reported basis, to $276 million in the first six months of 2026… |
| operating_income | positive | realized | +1.4% | Health & Biosciences Segment Adjusted Operating EBITDA increased $28 million, or 11% on a reported basis, to $290 million in the first six… |
| operating_income | positive | realized | +0.8% | Scent Segment Adjusted Operating EBITDA increased $16 million, or 6% on a reported basis, to $275 million in the first six months of 2026… |